Phase III: SG-INSIGHT
Get an overview of the ongoing Phase III of Singapore's NPM programme — from its key goals to how genomic sequencing is being integrated into real-world clinical settings across Singapore.
From World-class to World-leading
Phase III of the National Precision Medicine (NPM) programme marks a pivotal moment where scientific advances are translated from research pilots to population mainstreaming. Our ambition has expanded in both scale and scope, including up to 10% of Singapore’s population receiving medical treatments and healthcare services.
Phase III shifts to patients receiving medical care across all three of Singapore’s healthcare clusters: NHG Health, NUHS, and SingHealth. Studying patients with healthcare conditions and receiving clinical treatments allows the complete programme to address the entire healthcare life-course, from early to late-stage disease, in real-world settings.
Furthermore, the falling costs of genetic sequencing and information technology may mean that it may soon make economic and clinical sense for each patient’s entire genome to be sequenced once and analysed as needed across their lifetime, a concept we term as SOAR (Sequence Once, Analyse Repeatedly).
Phase III Goals
Generate whole genome sequences of about 10% of Singapore’s resident population.
Establish Genomic Innovation Hubs in each healthcare cluster to identify genetic conditions that may be suitable for eventual mainstreaming.
Demonstrate large-scale whole genome sequencing clinical utility, starting with pharmacogenomics and expanding to other use-cases as evidence emerges.
Advance the PRECISE-SG100K (Phase II) resource with new multi-omic, imaging and digital phenotyping data, etc.
Build a secure and accessible platform connecting genomic, clinical, and phenotypic data to drive research and clinical outcomes.
Build a community of engaged patient participants who actively contribute to genomic research and healthcare innovation.